Alendronate 10mg tablets vs placebo
Polypharmacy guidance: realistic prescribing
Study population:
Post-menopausal women
a) For primary prevention average T-score was within 2 standard deviations of the mean for bone density
b) For secondary prevention in women who had experienced previous vertebral compression fractures
Comments:
Age range 42-85 but >62 for secondary prevention
These NNTs apply to the first 5 years of treatment only
| Outcome | Duration | NNT | Annualised NNT | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertebral secondary prevention | 60 months (5 years) |
|
|
||||||||||||||||||||||||||||
| Non-vertebral secondary prevention | 60 months (5 years) |
|
|
||||||||||||||||||||||||||||
| Hip secondary prevention | 60 months (5 years) |
|
|